Nephrologists are most anticipating sparsentan (Travere, co-marketed with Vifor in EU), with Vertex’s pipeline product VX-147 following closely behind –...
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and...
Spherix’s third bi-annual audit analyzed the charts of 1,002 CKD non-dialysis patients with moderate to severe kidney disease treated by...
Release of second annual EU5 research on IgA nephropathy highlights unmet needs, regional diagnosis and treatment trends, and awareness of...
Launch data tracking the market receptivity for Korsuva (Vifor/Cara Therapeutics), Kerendia (Bayer), Lupkynis (Aurinia Pharmaceuticals), and Tarpeyo (Calliditas) unveils gaps...
Recent endorsement of Evrenzo by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further...
Life science launch analyst Spherix reached that conclusion after analyzing the results of two surveys—one of 104 U.S. nephrologists and...
Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa., June 17, 2022 /PRNewswire/ —With the approvals...
Cross-specialty analysis on CKD and DKD patient management and evolving use of SGLT2 inhibitors shows market may be poised for...
Diagnosis, treatment, management, the increasing role of genetic testing, and the future promise of gene therapy captured in new report...
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice...
The first IgA Nephropathy (Japan) study, due to release later this summer, pairs with other studies in the EU5 and...
